Review finds selexipag is well tolerated in children

Robyn Kalda
Mar 16
1 min read

A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies. About 60% of pediatric patients had side effects, mostly mild.

Read the Pediatric Cardiology article

Recent Posts

Environmental triggers may contribute to heritable PAH

This study tried to identify new environmental triggers or genetic causes in heritable pulmonary arterial hypertension. They found several potential genes for further exploration, but they also found

Time to diagnosis matters for patients with PAH

This study identified factors associated with a delayed diagnosis of PAH and found that earlier diagnosis (<6 months) and treatment initiation were associated with significantly improved survival. Mor

Sotatercept might help treat portopulmonary hypertension

Patients with portopulmonary hypertension were not included in clinical trials for sotatercept. This case report found that sotatercept helped one patient with portopulmonary hypertension, who was the

Comments